Can a Two-Dose drug delay type 1 diabetes as well as a 14-Day treatment?

NCT ID NCT07216391

Not yet recruiting Disease control Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares two drugs, ATG and teplizumab, to see if they can delay or prevent type 1 diabetes in people who are at high risk. About 60 participants aged 4 to 35 will receive either two infusions of ATG or 14 daily infusions of teplizumab. Researchers will monitor them for at least a year to see how well each drug works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Antithymocyte Globulin (ATG) or Teplizumab
What this could lead to: If successful, this could offer another treatment option to delay the onset of type 1 diabetes in people at high risk.
What could go wrong: This is a small, early-phase study with only 60 participants. It may not show a clear benefit, and the effects may not last long-term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES MELLITUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 1 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 1 DIABETES MELLITUS

Contacts and locations

Locations

University of Florida

Gainesville, Florida, 32610, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.